-
Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026
Survival estimate remained at 48% between years two and three, extending evidence of durable benefit Results observed
Lifestyle Content
Technology
-
From Abu Dhabi to the World: Chery Group Reaffirms Its Commitment to FREELANDER and a New Benchmark for Premium Brands
-
E-Brokerage Market Projected to Reach $34.6 Billion by 2034 as Record Retail Trading Volumes Lift Platforms
-
Troman’s Trident demonstrates ability to extinguish bus battery fire in live-fire testing.
-
Three new directors elected to Scoular’s Board of Directors
-
Concierra Legal Announces Founder’s 15th Consecutive Texas Super Lawyers Selection with Top 50 Women and Top 100 DFW Honors
Entertainment
-
Tyrannus Angel Awards Announces 2026 Official Selection Honoring the Human Spirit in AI Film
-
Davis & The Love Announce New Album Songs We Wrote About You, Arriving October 16
-
The Empty Pockets Announce $285,000 “Billionaire Pricing” for Their New Album
-
Georgia’s Magical Nights of Lights Bigger and Brighter for 2026
-
Migguel Anggelo Celebrates the Immigrant Experience, Latino Identity, and the Power of Iconic Latin Rhythms During Hispanic Heritage Month
Health
-
Edmunds ranks the best SUVs for parents
-
The metro areas with America’s worst commutes aren’t the ones with the worst insurance bills
-
Why more policyholders are exploring what their life insurance is worth beyond surrender value
-
How much square footage a $500K housing budget buys across US metros
-
The new meaning of staying put as job tenures rebound
